Etoricoxib

Polyneuropathy

Ruhr University of BochumSmall moleculePhase 2Dormant

CCC

53/ 100

Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence: 38/ 100
Competitive Position: 95/ 100

Competitive context

32 Active assets in the Polyneuropathy cohort.

Asset / Sponsor	Phase	Rating
Pregabalin University of Rochester	Phase 4	A
LIDOCAINE University of Utah	Phase 4	BBB
Nabiximols VA Office of Research and Development	Phase 3	BBB
Eloxatin Tanta University	Phase 3	BBB
LIDOCAINE University Health Network, Toronto	Phase 3	BB

View all 50 →

Same molecule, other indications

Etoricoxib is also rated in:

osteoarthritisDormant

BB

Indicative ·

68 / 100

postherpetic neuralgiaDormant

BB

Indicative ·

66 / 100

Chronic Low Back PainDormant

BB

Indicative ·

65 / 100

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.